Latest press releases
A-TANGO – An EU-funded clinical Phase II study gives cirrhosis patients new hope
About EASL and the A-TANGO Consortium The A-TANGO Consortium, a five-year project, consists of 14 institutions across eight countries in Europe. It aims to perform Phase II clinical studies of an innovative…
COVID-Hep Registry relaunches version 2.0, with EASL support
At EASL, we are pleased to support the relaunch of the international reporting registry COVID-Hep 2.0. Accordingly, EASL encourages healthcare professionals to share the registry among its networks. Every individual and centre…
On Rare Disease Day, we honour the many, the strong, the proud
EASL honours Rare Disease Day, taking place this Sunday, 28 February. An estimated 300 million people globally are affected by rare diseases – diseases of which 6,000 have been identified.
EASL policy statement on the use of COVID-19 vaccines in people with chronic liver disease, hepatobiliary cancer, and liver transplant recipients
By end-January 2021, COVID-19, the systemic disease caused by the pandemic spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), accounted for 2.2 million deaths worldwide and for 100 million individuals infected,…
New breakthrough in advanced HCC
Digital Liver Cancer Summit 2021: New follow-up data from a landmark study of liver cancer patients treated with a combination of atezolizumab and bevacizumab has shown the longest ever survival time in…
Global survey reveals heavy toll of COVID-19 first wave on liver cancer care
Digital Liver Cancer Summit 2021: A global survey assessing the impact of COVID-19 on liver cancer has revealed delays in the screening, diagnosis, and treatment of the disease, with experts issuing stark…
